Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-21T13:21:40.005Z Has data issue: false hasContentIssue false
  • English
  • Français

Crystal and X-ray powder diffraction data for cefotaxime sodium salt, C16H16N5NaO7S2

Published online by Cambridge University Press:  10 January 2013

Héctor Novoa de Armas ,
Eladio Pardillo-Fontdevila  and
Ramón Pomés Hernández
Héctor Novoa de Armas*
Affiliation:
Center of Pharmaceutical Chemistry, P.O. Box 16042, Havana, Cuba
Eladio Pardillo-Fontdevila
Affiliation:
Center of Pharmaceutical Chemistry, P.O. Box 16042, Havana, Cuba
Ramón Pomés Hernández
Affiliation:
National Center for Scientific Research, P.O. Box 6990, Havana, Cuba
*
a)Author to whom correspondence should be addressed. Present address: Laboratorium voor Analytische Chemie en Medicinale Fysicochemie. Katholieke Universiteit Leuven (KUL). Van Evenstraat 4, 3000 Leuven, Belgium. E-mail: hector.novoa@farm.kuleuven.ac.be
Get access Rights & Permissions [Opens in a new window]

Abstract

An indexed powder diffraction pattern and related crystallographic data are reported for cefotaxime sodium salt: 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[(2amino-4-thiazolyl)(methoxyimino)-acetyl]amino]-8-oxo, monosodium salt, [6R−[6α,7β(Z)]], C16H16N5NaO7S2. The unit cell dimensions were determined from diffractometer methods, using monochromatic CuKα1 radiation, and evaluated by indexing programs. The monoclinic cell found for cefotaxime sodium was a=13.063(2) Å, b=8.916(2) Å, c=9.726(2) Å, β=107.34(2)°, Z=2, space groups: P21 (No. 4) or P21/m (No. 11), Dx=1.467 g/cm3.

Type
Research Article
Information
Powder Diffraction , Volume 14 , Issue 2 , June 1999 , pp. 142 - 144
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

de Wolff, P. M. (1968). “A simplified criterion for the reliability of a powder pattern indexing,” J. Appl. Crystallogr. 1,108.CrossRefGoogle Scholar
Martindale: The Extra Pharmacopoeia (1989). 29th ed. Reynolds, J. E. F. (Ed). The Pharmaceutical Press, London, pp. 151–156.Google Scholar
Mighell, A. D., Hubbard, C. R., and Stalick, J. K. (1981). NBS*AIDS80: A Fortran Program for Crystallographic Data Evaluation. Natl. Bur. Stand. Tech. (U.S.). Note No. 1141. (NBS*AIDS83 is an expanded version of NBS*AIDS80.)CrossRefGoogle Scholar
Siemens D5000/DIFFRAC-AT Version 3.2. (1993). Siemens Analytical X-ray Instruments, Inc., Karlsruhe, Germany.Google Scholar
Smith, G. S., and Snyder, R. L. (1979). “FN: A criterion for rating powder diffraction patterns and evaluating the reliability of powder pattern indexing,” J. Appl. Crystallogr. 12, 60–65.CrossRefGoogle Scholar
U.S. Pharmacopoeia National Formulary. USP XXII. (1990). US Pharmacopoeial Convention, Easton, PA.Google Scholar
Werner, P. E., Eriksson, L., and Westdahl, M. (1985). “TREOR: A semi-exhaustive trial-and-error powder indexing program for all symmetries,” J. Appl. Crystallogr. 18, 367–370.CrossRefGoogle Scholar